GlassScriptPhysician profile
Saul Wasserman
NPI 1174625966
$651.65
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $557 · 2020: $95.13.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $139.71 | 2019-2020 | |
| Lundbeck LLC | $127.44 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $117.64 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $98.13 | 2019 | |
| Allergan, INC. | $43.54 | 2019 | |
| Bausch Health US, LLC | $29.26 | 2019-2020 | |
| Shire North American Group INC | $26.71 | 2019 | |
| Neurocrine Biosciences, INC. | $24.72 | 2020 | |
| Vanda Pharmaceuticals INC. | $18.13 | 2019 | |
| Ironshore Pharmaceuticals INC. | $16.90 | 2019 | |
| Neuronetics, INC. | $9.47 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Saul Wasserman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.